Including pain, fatigue and physical function when assessing patients with early rheumatoid arthritis provides a comprehensive picture of disease burden

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be

Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be